Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBT Margin (2016 - 2025)

Historic EBT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to 10.79%.

  • Ascendis Pharma A's EBT Margin rose 107100.0% to 10.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 28.7%, marking a year-over-year increase of 745200.0%. This contributed to the annual value of 29.53% for FY2025, which is 731100.0% up from last year.
  • Ascendis Pharma A's EBT Margin amounted to 10.79% in Q4 2025, which was up 107100.0% from 26.86% recorded in Q3 2025.
  • Ascendis Pharma A's EBT Margin's 5-year high stood at 10.79% during Q4 2025, with a 5-year trough of 13154.79% in Q2 2021.
  • Over the past 5 years, Ascendis Pharma A's median EBT Margin value was 280.17% (recorded in 2024), while the average stood at 1790.55%.
  • In the last 5 years, Ascendis Pharma A's EBT Margin tumbled by -65365500bps in 2021 and then skyrocketed by 118339200bps in 2022.
  • Over the past 5 years, Ascendis Pharma A's EBT Margin (Quarter) stood at 123.27% in 2021, then crashed by -616bps to 882.6% in 2022, then soared by 97bps to 26.79% in 2023, then grew by 20bps to 21.5% in 2024, then surged by 50bps to 10.79% in 2025.
  • Its EBT Margin was 10.79% in Q4 2025, compared to 26.86% in Q3 2025 and 22.15% in Q2 2025.